National Class 1 Biological New Drug Eponemin for Injection (Shaite®) was approved for marketing on November 1, 2023. As the world's first approved DR4/DR5 agonist, its marketing marks a big step forward in the field of multiple myeloma treatment in China. The online salon of Shaite, organized by Chengdu Hi-Tech Medical Association, will be held in Chengdu on June 4, 2024, hoping to help experts to better apply this domestic original biological new drug and bring new hope to patients. Professionals and technicians engaged in the field of myeloma, basic research workers in the related fields of scientific research institutions, clinical medicine, pharmacy and other professional workers in the related fields of medical institutions attended the meeting.